cancer outcomes (OS, DFS, RFS) . Because of the differences in disease type, populations, assay, and definitions of expression, I am concerned that a pooled analysis might be very limited. In particular, the authors have not addressed how differences in assay or detection threshold could introduce bias?
2. In addition to hazard ratios, to understand the clinical relevance of any associations found, it would be helpful to also report the association with absolute risk. Did the authors look at this? At a minimum, please include the rates of event outcomes for each study.
3. For the 27 excluded studies owing to lack of survival data, were the findings null? Is there a risk the the exclusion of these studies might have biased the study toward more positive findings? 4. Why was the Asian subgroup studied and not other racial/ethnic groups? Was there some prior reason to suspect that the association of miRNA might differ for this population? 5. The findings for breast cancer suggest that there is possibly heterogeneity in the association of miRNA and OS by disease type. This raises a concern about the pooling of these types in the other analyses. How can we interpret the other analyses if effects differ by disease type? The authors should provide justification for this in the discussion.
6. Please include study sample sizes with all forest plots.
VERSION 1 -AUTHOR RESPONSE
Reviewer Name Jiucun Wang Institution and Country Fudan University, P.R.China Please state any competing interests or state "None declared": None declared 1. In the section of Introduction: miRNA can regulate both the transcriptional and posttranscriptional levels of target genes, thus, the introduction of miRNA in regulating transcriptional level of genes should not be omitted.
Re: Thank you for your professional and kindly suggestion. We have added that miRNA regulates transcriptional level of genes in our introduction, "A newly identified function for miRNAs was also reported, where gene expression was regulated at the transcriptional level [7] ." with reference. (Line 6, Introduction) 2. In the section of Methods: 1) Search strategy:
The studies published in Chinese should also be included because those data acquired from Chinese population are important for understanding the feature of miR-205 of not only Chinese ethnicity but also Asian populations in this meta-analysis.
Re: Thank you for your professional and kindly marking. We have added that "In addition, we searched for studies published in Chinese in order to comprehensively understand the role of miR-205 in cancer. However, there were no Chinese studies on the association of miRNA-205 expression with cancer prognosis."(Line 8, Search strategy)
2) Quality assessment: The sensitivity analysis should be performed when recruiting studies to avoid bias in results by some low-quality studies.
Re: Thank you for your kindly marking. We have followed your guidance and performed sensitivity analyses according to your requirements: "Sensitivity analyses were also performed to avoid a bias in the results due to certain low-quality studies (Figures 5A and 5B) ."(Line 6, Quality assessment) and "In the studies of OS and DFS/RFS, our sensitivity analyses do not materially change the results by the inclusion of any individual study (Figures 5A and 5B) , indicating that no single study influenced the pooled HR or the 95% CI, significantly."(Sensitivity analyses, Results)
3) Data extraction When extracting data, age, an factor closely correlated with cancer, should also be included in each population.
Re: Thank you for your professional suggestion, we have included the factor "age" when extracting data(Line 6, Data extraction) and added median or mean age of patients in Table 1. 3. In the section of Results: Overall survival associated with miRNA-205 expression: The authors claimed "A total of 14 articles were involved in OS analysis with a random-effects model because of observed significant heterogeneity". What are the resourses of heterogeneity?
Re: Thank you for your professional and kindly marking. "The heterogeneity test for pooled HRs was verified by Cochran Q-test and was quantified by Higgins I-squared statistic (I2). If significant heterogeneity was observed (P < 0.10 or I2 > 50%), a random-effects model was applied, otherwise the fixed-effects model was used. A total of 14 articles were involved in OS analysis (Table 3 and Fig. 2) with a random-effects model because of observed significant heterogeneity (P < 0.001, I2 = 76.8%)." Further, we conducted subgroup analyses to explore the causes of heterogeneity. "The outcome of 4 studies in breast cancer subgroup indicated that elevated miRNA-205 significantly correlated with a better OS (pooled HR=0.78, 95% CI: 0.67-0.91) by a fixed-effects model because of low heterogeneity among studies (P= 0.199, I2= 35.5%) . No other subgroups exhibited any significant results by stratified analyses." Therefore, we consider that the resourses of heterogeneity may be highly associated with different characteristics patients, like disease type, populations. In addition, heterogeneity may also result from differences in the intensity of intervetions or differences in underlying risk between studies of different sizes.
Reviewer Name Stephanie Kovalchik Institution and Country RAND Corporation United States
Please state any competing interests or state "None declared": None declared
The current form of the paper has numerous grammatical errors, which made it difficult to read.
Re: Thank you for your professional and kindly marking. I am so sorry not to have edited this manuscript carefully enough. We have reconsidered the grammar of each sentence and the spelling of each word. Moreover, we have asked a native speaker of English to help us further improve this article, including the reconsideration of grammar for each sentence and the simplification of language expression.
1. The authors have performed a meta-analysis and systematic review to estimate the association between miRNA-205 and several cancer outcomes (OS, DFS, RFS). Because of the differences in disease type, populations, assay, and definitions of expression, I am concerned that a pooled analysis might be very limited. In particular, the authors have not addressed how differences in assay or detection threshold could introduce bias?
Re: Thank you for your professional and kindly marking. First, the current data provided by published studies is insufficient to make this meta-analysis focus on a certain kind of human cancer. Fortunately, the underlying relationships between survival and miR-205 is indeed well studied in different kinds of cancers, therefore it is appropriate to put together studies from different cancer sites for a meta-analysis. Because of the relatively low number of enrolled studies, it seems to be premature to discuss the scope of clinical application for miR-205 as a prognostic tumor biomarker. However, more and more studies have confirmed the significant relationship between miR-205 expression and cancer prognosis. Moreover, miRNAs are more stable and not easily degraded compared to mRNAs. They exhibit a special expression profile in various normal and malignant tissues, which can be accurately detected and quantified by qRT-PCR not only in frozen or fresh tissues, but also in formalin-fixed paraffin-embedded tissues. Thus, if the accurate prognostic role and clinical application scope of miR-205 can be clarified, it may be a promising tumor biomarker with great value in clinical application. Second, detection bias refers to systematic differences between the comparison groups in outcome assessment, for example, differences in assay or detection threshold. Due to the lack of global uniform of miRNA-205 threshold, different researchers applied different cutoff values of miRNA-205, such as mean or median. This subjective outcome might lead to a misestimate and confound the effectiveness of miRNA-205 as a tumor prognostic factor. Therefore, a unified standard of miRNA-205 detection threshold is urgently needed.
Re: Thank you for your professional suggestion. The data from Kaplan-Meier curves of included studies were described as the type of time-to-event. The most appropriate way of summarising timeto-event data is to use methods of survival analysis and express the treatment effect as a hazard ratio. Hazard is similar in notion to risk, but is subtly different in that it measures instantaneous risk and may change continuously (for example, your hazard of death changes as you cross a busy road). A hazard ratio is interpreted in a similar way to a risk ratio, as it describes how many times more (or less) likely a participant is to suffer the event at a particular point in time if they receive the experimental rather than the control intervention. When comparing treatments in a trial or metaanalysis a simplifying assumption is often made that the hazard ratio is constant across the follow-up period, even though hazards themselves may vary continuously. This is known as the proportional hazards assumption. Moreover, due to the individual outcomes were reported by HRs or extracted from K-M curves, accurate event outcomes were not provided in the majority of included studies. Therefore, it"s difficult to include the rates of event outcomes.
3. For the 27 excluded studies owing to lack of survival data, were the findings null? Is there a risk the the exclusion of these studies might have biased the study toward more positive findings?
Re: Thank you for your professional and kindly marking. By quality assessment, we excluded the 27 low-quality studies due to lack of survival data such as hazards and K-M curves, and the findings were null. In addition, we carefully assessed these literatures by full texts in order to reduce citation bias as far as possible. Therefore, there might be a very low risk that the exclusion of these studies might have biased the study toward more positive findings. 4. Why was the Asian subgroup studied and not other racial/ethnic groups? Was there some prior reason to suspect that the association of miRNA might differ for this population?
Re: Thank you for your professional marking. The majority of 17 eligible literatures were focused on Caucasians while there were 3 on Asians from China, and no eligible studies on other racial/ethnic groups were found. Therefore, there remained only 2 main ethnic groups in subgroup analysis. Moreover, we conducted subgroup analysis on the basis of different ethnic characteristics in order to investigate if there was a potential relationship between certain ethnicity and survival outcome, however, there has been no evidence to prove the association of miRNA might differ for Asian population.
5. The findings for breast cancer suggest that there is possibly heterogeneity in the association of miRNA and OS by disease type. This raises a concern about the pooling of these types in the other analyses. How can we interpret the other analyses if effects differ by disease type? The authors should provide justification for this in the discussion.
Re: Thank you for your kindly and professional reminding. We have provided justification for this in the discussion: "Fourth, heterogeneity existed in the total OS and DFS/RFS analyses. The heterogeneity of the population was probably due to the different characteristics of the patients such as age, race, disease type, pathological type, the cut-off value of miRNA-205 expression, and so on. For instance, when we stratified OS studies according to the disease type, heterogeneity disappeared in the breast cancer subgroup (P = 0.199, I2 = 35.5%). Heterogeneity was also reduced in the adenocarcinoma subgroup when the DFS/RFS studies were classified by the pathological type (P = 0.116, I2 = 45.9%)." 6. Please include study sample sizes with all forest plots.
Re: Thank you for your professional suggestion. We have followed your guidance to improve the quality of our plots.
VERSION 2 -REVIEW

REVIEWER
Jiucun 
GENERAL COMMENTS
The authors present a meta-analysis to examine the prognostic value of miRNA-205 for cancer in general and for specific types of cancer. They conclude that the expression of miRNA-205 might be a clinical useful biomarker for breast cancer and adenocarcinoma.
I have a few major concerns with the authors' methodology and presentation.
1. There is a considerably amount of heterogeneity in nearly all of the meta-analyses performed. This raises concerns about the comparability of the studies included. Even within the disease subgroups, study findings are highly inconsistent. Unless there are some explanatory factors that the authors can introduce into the analysis, I would be very skeptical of drawing a conclusion from these findings.
2. There are numerous grammatical errors and awkward phrasing throughout the paper that made it difficult to read.
3. The PRISMA flow diagram is missing a count for "Studies included in qualitative synthesis".
4. In the statistical analysis, the authors mention excluding studies for lack of survival data. The way things are worded it is not clear if they had to have all of "hazard ratio, CI, and survival curve" or just one of these.
5.
On page 19, I think the authors intend something else than "controversial data". 6. On page 21, the authors cannot conclude that "publication bias did not exist". This should be re-stated to say that there was no evidence of publication bias. 7. The "Conclusions" subsection has several problems. First, "more suitable" than what? This phrasing implies a comparison but none is made. Also, how can the authors say that the predictive value of the marker has been demonstrated then in the next sentence say that there is not sufficient evidence to make this conclusion? This is confusion and should be clarified.
VERSION 2 -AUTHOR RESPONSE
Thank you for your professional suggestion. First, in order to clarify the comparability of the studies included, we added the assessment of study quality by using the Cochrane Risk of Bias tool and grading each potential source of bias as low, high, or unclear risk of bias (www.cochranehandbook.org) in the Quality assessment (Figures 6 and 7) and rewrote the conclusions, "In summary, our findings suggest that miRNA-205 is a potential biomarker and that the detection of its expression in patients with breast cancer may allow for accurate prognostic predictions. Moreover, further investigation of the relationship between miR-205 expression and cancer prognosis is required to enable its future clinical application. "
